| Literature DB >> 29454748 |
Norimichi Chiyonobu1, Shu Shimada2, Yoshimitsu Akiyama2, Kaoru Mogushi2, Michiko Itoh3, Keiichi Akahoshi4, Satoshi Matsumura4, Kosuke Ogawa4, Hiroaki Ono4, Yusuke Mitsunori4, Daisuke Ban4, Atsushi Kudo4, Shigeki Arii4, Takayoshi Suganami5, Shoji Yamaoka6, Yoshihiro Ogawa7, Minoru Tanabe4, Shinji Tanaka8.
Abstract
Metabolic syndrome is a newly identified risk factor for hepatocellular carcinoma (HCC); however, tumor-specific biomarkers still remain unclear. We performed cross-species analysis to compare gene signatures of HCC from human patients and melanocortin 4 receptor-knockout mice, which develop HCC with obesity, insulin resistance, and dyslipidemia. Unsupervised hierarchical clustering and principle component analysis of 746 differentially expressed orthologous genes classified HCC of 152 human patients and melanocortin 4 receptor-knockout mice into two distinct subgroups, one of which included mouse HCC and was causatively associated with metabolic risk factors. Nine genes commonly overexpressed in human and mouse metabolic disease-associated HCC were identified; fatty acid binding protein 4 (FABP4) was remarkably enriched in intratumoral activated hepatic stellate cells (HSCs). Subclones constitutively expressing FABP4 were established from a human HSC cell line in which expression levels of inflammatory chemokines, including IL-1A and IL-6, were up-regulated through NF-κB nuclear translocation, resulting in recruitment of macrophages. An immunohistochemical validation study of 106 additional human HCC samples indicated that FABP4-positive HSCs were distributed in tumors of 38 cases, and the FABP4-high group consisted of patients with nonviral and nonalcoholic HCC (P = 0.027) and with multiple metabolic risk factors (P < 0.001) compared with the FABP4-low group. Thus, FABP4 overexpression in HSCs may contribute to hepatocarcinogenesis in patients with metabolic risk factors by modulation of inflammatory pathways.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29454748 DOI: 10.1016/j.ajpath.2018.01.012
Source DB: PubMed Journal: Am J Pathol ISSN: 0002-9440 Impact factor: 4.307